GSK discontinues genital herpes vaccine after Phase III failure
This article was originally published in Scrip
Executive Summary
The most advanced vaccine in development to protect against genital herpes disease in woman, GlaxoSmithKline's Simplirix, has unexpectedly failed in a large Phase III trial, leading the company to discontinue its development.